Search

Search Constraints

You searched for: Author/Creator Jacobs, Alan

Search Results

3. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS. (April 2022)

4. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. (April 2021)

5. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. (December 2020)